Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma
-
Published:2024-07-07
Issue:7
Volume:12
Page:1508
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Díaz del Arco Cristina12ORCID, Estrada Muñoz Lourdes34, Cerón Nieto María de los Ángeles2, Molina Roldán Elena5ORCID, Fernández Aceñero María Jesús12ORCID, García Gómez de las Heras Soledad4ORCID
Affiliation:
1. Department of Legal Medicine, Psychiatry and Pathology, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain 2. Department of Pathology, Hospital Clínico San Carlos, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain 3. Department of Pathology, Rey Juan Carlos Hospital, 28933 Móstoles, Spain 4. Department of Basic Medical Sciences, School of Medicine, Rey Juan Carlos University, 28933 Móstoles, Spain 5. Biobank, Hospital Clínico San Carlos, 28040 Madrid, Spain
Abstract
Galectin-1 (Gal-1), a member of the human lectin family, has garnered attention for its association with aggressive behavior in human tumors, prompting research into the development of targeted drugs. This study aims to assess the staining pattern and prognostic significance of Gal-1 immunohistochemical expression in a homogeneous cohort of Western patients with gastric cancer (GC). A total of 149 cases were included and tissue microarrays were constructed. Stromal Gal-1 expression was observed to some extent in most tumors, displaying a cytoplasmic pattern. Cases with stromal Gal-1 overexpression showed significantly more necrosis, lymphovascular invasion, advanced pTNM stages, recurrences, and cancer-related deaths. Epithelial Gal-1 expression was present in 63.8% of the cases, primarily exhibiting a cytoplasmic pattern, and its overexpression was significantly associated with lymphovascular invasion, peritumoral lymphocytic infiltration, and tumor-related death. Kaplan/Meier curves for cancer-specific survival (CSS) revealed a significantly worse prognosis for patients with tumors exhibiting stromal or epithelial Gal-1 overexpression. Furthermore, stromal Gal-1 expression stratified stage III patients into distinct prognostic subgroups. In a multivariable analysis, increased stromal Gal-1 expression emerged as an independent prognostic factor for CSS. These findings underscore the prognostic relevance of Gal-1 and suggest its potential as a target for drug development in Western patients with GC.
Reference94 articles.
1. Epidemiology of stomach cancer;Ilic;World J. Gastroenterol.,2022 2. Shin, W.S., Xie, F., Chen, B., Yu, P., Yu, J., To, K.F., and Kang, W. (2023). Updated Epidemiology of Gastric Cancer in Asia: Decreased Incidence but Still a Big Challenge. Cancers, 15. 3. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration;Bray;Int. J. Cancer,2015 4. Bosman, F., Carneiro, F., Hurban, R., and Theise, N. (2019). WHO Classification of Tumours of the Digestive System, IARC. [4th ed.]. 5. Mantziari, S., St Amour, P., Abboretti, F., Teixeira-Farinha, H., Gaspar Figueiredo, S., Gronnier, C., Schizas, D., Demartines, N., and Schäfer, M. (2023). A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma. Cancers, 15.
|
|